Name: The unmet need in relapsed/refractory B-ALL is real, and urgent. We’re bringing data, and a plan, to potentially change that. Join us at our R&D Day on Oct 16 (NYC) To register ➡️… | Cellectis
Uploaded: 2025-10-13T15:50:40.075Z
Duration: 29 s
Channel: Cellectis
Description: The unmet need in relapsed/refractory B-ALL is real, and urgent. We’re bringing data, and a plan, to potentially change that. Join us at our R&D Day on Oct 16 (NYC) To register ➡️ cellectis@astrpartners.com

Cellectis

46,486 followers

1mo Edited

The unmet need in relapsed/refractory B-ALL is real, and urgent. We’re bringing data, and a plan, to potentially change that. Join us at our R&D Day on Oct 16 (NYC) To register ➡️ cellectis@astrpartners.com

1 Comment

Transcript

Every patient deserves the same chance, but that's hardly the case in leukemia. It's like this where precision meets purpose, hope takes form. Last, Mussel is rewriting what's possible in relapsed or refractory BL October the 16th. Come and see the data unfold. Join us in person at Selects R&D Day in New York City. Thank you.

Karim Hatem

Senior Partner, KEA & Partners - Ylios

1mo

Great Talk Andre Choulika Ph.D. ! I hope I could have been in New York

1 Reaction

To view or add a comment, sign in

Explore content categories